Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Allogeneic, BCMA, CAR-T, CD19 Oct 02 | 2020Precision Biosciences Highlights First Patient Dosed with BCMA CAR-T PBCAR269A; PBCAR0191 Clinical Updates Delayed to YE; Q2 2020 Earnings SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Sep 30 | 2020Legend Biotech Highlights FDA Filing of Cilta-Cel by YE 2020; Q2 2020 Earnings SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA Sep 22 | 2020BMS and bluebird bio Receive Priority Review for Ide-cel; PDUFA Projected Around March 27, 2021Access Free Blast
Free
Posted in: Autologous, CD19, CD22 Sep 21 | 2020Updated AUTO3 Ph1/2 ALEXANDER Results; ESMO 2020 Investor Call SummaryAccess Free Blast
Free
Posted in: CAR-T, CD123, CD22, CS1 Sep 18 | 2020Thoughts on Cellectis’s CAR-T Program; Potential UCARTCS1 Protocol Changes; Q2 2020 Earnings CallAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19, CD22 Sep 08 | 2020Thoughts on Autolus's CAR-T Program; Q2 2020 Earnings CallAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Sep 04 | 2020Gilead Highlights No Impact of COVID-19 on Yescarta Sales; Two New LCM Initiatives for Yescarta; Q2 2020 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T Sep 03 | 2020bluebird bio Highlights Ide-cel Resubmission; Q2 2020 Earnings CallAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T, CD19 Sep 01 | 2020Thoughts on Allogene’s AlloCAR Program; Q2 2020 Earnings Call SummaryAccess Free Blast
Free
Posted in: BCMA, CAR-T, CD19 Sep 01 | 2020BMS Highlights Ide-cel FDA Re-submission; Q2 2020 Earnings CallAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Aug 31 | 2020Thoughts on Gilead's Recent FDA Approval for Tecartus (KTE-X19) in R/R Mantle Cell LymphomaAccess Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jul 30 | 2020BMS and bluebird bio Resubmit Ide-cel to FDA; Dynamic H1 2021 BCMA Launch Environment Expected with JanssenAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Jul 03 | 2020Novartis Ph1b PORTIA Results Presented at Virtual AACR IIAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19, CD22 Jul 03 | 2020Two New Gracell Early Ph1 Trials in MM and NHL PostedAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, CD22 Jun 17 | 2020Novartis Discusses Their Activated Rapid Manufacturing Program and Kymriah in the Community SettingAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jun 12 | 2020Gilead Announces EMA Approval for End-to-End Yescarta CAR-T Manufacturing at Amsterdam FacilityAccess Free Blast
Free
Posted in: Allogeneic, CAR-T, CD19 Jun 09 | 2020New Pivotal ALLO-501A (ALPHA-2) Trial in DLBCL PostedAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19, CD22 Jun 05 | 2020Autolus Ph1 ALEXANDER Results and ASCO 2020 Investor Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, CAR-T, CD19 Jun 01 | 2020Allogene ALLO-501 Ph1 ALPHA Results and ASCO 2020 Investor Call SummaryAccess Free BlastFree
Posted in: Autologous, CD19 May 29 | 2020New Autolus AUTO1 Pivotal Trial in Adult ALL PostedAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.